Nuoxin Chuanglian

Founded in 2015, Nuoxin is a life sciences marketing solutions company based on AI technology. As a leading enterprise in digital promotion for the domestic pharmaceutical industry, leveraging cutting-edge semantic understanding and deep learning algorithms, it has developed a proprietary intelligent business operations platform that integrates into the core business processes of pharmaceutical companies, helping them achieve more efficient promotion while ensuring compliance. In 2020, the company's core business maintained a high growth rate of over 500%, covering 100 drug categories, with over 200,000 highly active physicians and contractual revenue exceeding 100 million RMB. Since its establishment, Nuoxin Chuanglian has focused on providing digital promotion solutions for pharmaceutical companies, applying "data analysis/management tools/business consulting + execution" to pharmaceutical enterprises. Utilizing leading artificial intelligence technology and more precise online promotion solutions, it is committed to helping pharmaceutical companies transform traditional medical promotion models and establish more compliant and efficient digital systems. Additionally, by providing physicians at all levels with quality information resources and services, Nuoxin Chuanglian helps clinicians obtain professional information and use professional tools more efficiently and conveniently, thereby improving diagnostic and treatment standards. Furthermore, Nuoxin Chuanglian provides a platform for interaction between patients and doctors, helping both parties achieve chronic disease management and improve patients' quality of life. Relying on its technological and market advantages, Nuoxin Chuanglian acts as a bridge, "serving two parties at once," connecting the vast pharmaceutical promotion and sales market with millions of medical institutions and physicians, committed to building a network between pharmaceutical companies and doctors, enabling pharmaceutical companies to conduct medical promotion with doctors more efficiently. At the same time, it can move doctors from traditional offline settings to online, thereby achieving higher efficiency, lower costs, and greater transparency. To date, Nuoxin Chuanglian has collaborated with over 20 international pharmaceutical companies including Pfizer, AstraZeneca, Novartis, and Bayer, covering over 100 drug types and 200,000 physicians, with annual business growth of 200-500%. In September 2020, the company secured a new financing round of 200 million RMB, led by Sequoia Capital, with participation from Matrix Partners and Morningside, and previous annual rounds have included participation from top domestic and international investment institutions and strategic investors. Nuoxin is committed to reshaping the pharmaceutical chain through advanced technology and products, helping enterprises generate revenue, helping doctors improve treatment standards, and helping patients live happier lives, truly realizing technology serving business and creating value for society. Recent investment and financing news reports about the company include: Dongmao Network exclusive | Nuoxin Chuanglian completes financing of 200 million RMB led by Sequoia China, continuing to support pharmaceutical digital reform*| Based on big data providing intelligent marketing solutions for pharmaceutical companies, 'Nuoxin Chuanglian' secures tens of millions of USD in Series B+ financing* 36Kr exclusive | Addressing pain points in pharmaceutical marketing and doctors' information needs, 'Nuoxin Chuanglian' secures 15 million USD in financing from CCV and Volcano Stone*| Fengrui Research Institute - Learning investment through investment